Sec Form 3 Filing - Ross Michael A. @ 20/20 Biolabs, Inc. - 2026-02-17

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Ross Michael A. 2. Issuer Name and Ticker or Trading Symbol 20/20 Biolabs, Inc. [ AIDX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235 3. Date of Earliest Transaction (MM/DD/YY) 02/17/2026 (Street) GAITHERSBURG, MD20877 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A-2 Preferred Stock ( 1 ) ( 1 ) ( 1 ) ( 1 ) Common Stock 31 D Stock Option ( 2 ) $ 0.82 08/01/2019 07/31/2029 Common Stock 48,780 D Stock Option ( 3 ) $ 1.044 01/28/2021 01/27/2031 Common Stock 76,628 D Stock Option ( 4 ) $ 1.0643 ( 4 ) 02/01/2032 Common Stock 37,584 D Stock Option ( 5 ) $ 1.0643 02/01/2022 02/01/2032 Common Stock 37,583 D Stock Option ( 6 ) $ 1.74 ( 6 ) 01/01/2033 Common Stock 30,000 D Stock Option ( 7 ) $ 2.55 ( 7 ) 07/01/2034 Common Stock 30,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Ross Michael A. C/O 20/20 BIOLABS, INC. 15810 GAITHER ROAD, SUITE 235 GAITHERSBURG, MD20877 X Signatures /s/ Michael A. Ross 02/17/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date. ( 2 )On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant. ( 3 )On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant. ( 4 )On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months. ( 5 )On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant. ( 6 )On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months. ( 7 )On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.